Phase II Trial of Gliadel® plus O(6)-Benzylguanine (O(6)-BG) in Adults with Recurrent Glioblastoma Multiforme

PURPOSE: This phase II trial was designed to: define the efficacy of Gliadel® wafers in combination with an infusion of O(6)-BG that suppresses tumor O(6)-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent GBM for 5 days; and evaluate the safety of this combination therapy. PA...

詳細記述

保存先:
書誌詳細
主要な著者: Quinn, Jennifer A., Jiang, Sara Xiaoyin, Carter, James, Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Rich, Jeremy N., Gururangan, Sridharan, Friedman, Allan H., Bigner, Darell D., Sampson, John H., McLendon, Roger E., Herndon, James E., Threatt, Stevie, Friedman, Henry S.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2710963/
https://ncbi.nlm.nih.gov/pubmed/19188181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2130
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料